Thromboprophylaxis in Covid-19 Positive Pregnant Women

INTRODUCTION[|]Serious Covid-19 disease is often complicated by coagulopathy. Most of Covid-19-related deaths have been shown to be caused by extensive intravascular coagulation disorders. Our aim in this study is to examine the importance of thromboprophylaxis in Covid-19 positive pregnant women.[¤]METHODS[|]Pregnant women diagnosed with Covid-19 with the polymerase chain reaction test were retrospectively analyzed and treatment processes were evaluated.[¤]RESULTS[|]A total of 18 pregnant women were followed up with the diagnosis of Covid-19. The mean age of the patients was 28.90+-5.26 (18–41). Laboratory results revealed high CRP levels (11/18), lymphocytopenia (10/18) and increased neutrophil percentage (14/18). CT examinations were reported as widespread involvement findings (ground glass opacities - GGO) in 3 of 8 patients and mild fibrotic changes in 5 of the patients. Thromboprophylaxis was not applied in 4 outpatients however applied in 9/14 of the hospitalized patients. The average duration of drug use is 7.1 days (1–14). Average hospital stay is 3.3 days (2–16). The preferred dose is 40 mg 1x1/day. In a patient with suspected pulmonary embolism, 60 mg of 2x1/day enoxaparin was used. Maternal, fetal, and hemorrhagic complications were not observed. [¤]DISCUSSION AND CONCLUSION[|]Since there is a tendency to hypercoagulation in pregnancy, thromboembolic events are more common. Therefore, starting LMWH treatment before Covid-19 infection progresses could be beneficial for preventing embolic complications that may be fatal.[¤]

Abstract licence: CC BY-NC

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.